What is William Blair’s Estimate for NTLA FY2029 Earnings?
Equities researchers at William Blair issued their FY2029 earnings per share (EPS) estimates for shares of Intellia ...
Leerink Partnrs Weighs in on NTLA Q1 Earnings
Equities research analysts at Leerink Partnrs issued their Q1 2025 earnings estimates for Intellia Therapeutics in a research report issued to clients and investors on Thursday, February 27th. Leerink ...
Intellia Therapeutics price target lowered to $50 from $90 at Truist
Truist analyst Joon Lee lowered the firm’s price target on Intellia Therapeutics (NTLA) to $50 from $90 and keeps a Buy rating on the shares.